Read About Ocrevus Benefits and Important Treatment Considerations

Ocrevus, also known by its generic name ocrelizumab, is a disease modifying treatment used for specific forms of multiple sclerosis. It is a CD20 directed monoclonal antibody that works by reducing certain B cells involved in immune system activity. In the United States, current approval includes relapsing forms of MS and primary progressive MS in adults, as well as relapsing remitting MS in pediatric patients aged 10 years and older who weigh at least 25 kilograms.

Understanding Ocrevus Benefits and Uses

Ocrevus may help reduce disease activity in people with eligible forms of MS. Clinical studies have shown reductions in relapses, MRI measures of disease activity, and certain measures of disability progression in appropriate patient populations. For primary progressive MS, treatment has demonstrated an ability to slow some measures of disability progression compared with placebo.

Important points about its potential benefits include:

• It is used for relapsing forms of MS, including relapsing remitting disease and active secondary progressive disease in adults.
• It is approved for primary progressive MS in adults.
• It is approved in the United States for relapsing remitting MS in children aged 10 years and older who weigh at least 25 kilograms.
• Treatment is intended to reduce disease activity and help manage the progression of MS rather than provide an immediate cure.

Treatment schedules and administration depend on the formulation and prescribing instructions. Intravenous Ocrevus begins with two 300 mg infusions separated by two weeks, followed by 600 mg infusions every six months.

Important Treatment Considerations and Safety

Before treatment begins, healthcare professionals generally assess factors that could affect safety. The FDA prescribing information recommends hepatitis B screening, quantitative immunoglobulin testing, liver function testing, and review of vaccinations before starting treatment. Patients should also be assessed for active infection before each infusion.

Key considerations include:

• Infusion reactions can occur, so premedication and monitoring are used with intravenous administration.
• Ocrevus can increase the risk of infections, including serious infections in some patients.
• Active hepatitis B infection is a contraindication to Ocrevus treatment.
• Immunoglobulin levels may decrease during treatment and may require monitoring.
• Live or live attenuated vaccines are generally not recommended during treatment and until B cell recovery after discontinuation.
• Patients should promptly discuss new or persistent symptoms, including signs of infection, with their healthcare professional.
• The prescribing information also includes warnings concerning progressive multifocal leukoencephalopathy, malignancies, immune mediated colitis, and liver injury.

The decision to use Ocrevus depends on the type of MS, medical history, infection status, vaccination history, laboratory results, and other individual factors. Patients should discuss potential benefits and risks with a qualified healthcare professional before starting, changing, or stopping treatment. This information is provided for educational purposes only and is not a substitute for individualized medical advice.